quinn emanuel trial lawyers | silicon valley

555 Twin Dolphin Drive, 5th Floor, Redwood Shores, California 94065-2139 | TEL: (650) 801-5000 FAX: (650) 801-5100

WRITER'S DIRECT DIAL NO. (650) 801-5055

WRITER'S INTERNET ADDRESS briancannon@quinnemanuel.com

March 16, 2011

VIA E-MAIL

Karl A. Rupp Kendall Law Group, LLP 3232 McKinney Ave., Suite 700 Dallas, TX 75204 krupp@kendalllawgroup.com

Bradley E. Beckworth
Derek T. Gilliland
Nix Patterson & Roach, LLP
205 Linda Drive
Daingerfield, TX 75639
bbeckworth@nixlawfirm.com
dgilliland@nixlawfirm.com

Alan D. Albright Bracewell & Giuliani LLP 111 Congress Ave., Suite 2300 Austin, TX 78707 alan.albright@bgllp.com

Bradley J. Benoit
Heath A. Novosad
Ralph D. McBride
Stephen B. Crain
Bracewell & Giuliani LLP
711 Louisiana St., Suite 2300
Houston, TX 77002
brad.benoit@bgllp.com
heath.novosad@bgllp.com
ralph.mcbride@bgllp.com
stephen.crain@bgllp.com

Re:

Troll Busters, LLC v. Roche Diagnostics GMBH, et al. Case No. 11-CV-0056-IEG (WVG) (S.D. Cal.)

Dear Counsel:

We represent the Roche Defendants in the above-captioned matter, and we are writing on behalf of several defendants, including Eurogentec North America Inc., Clontech Laboratories, Inc., Integrated DNA Technologies (IDT), Life Technologies Corporation, Qiagen NV, Thermo

quinn emanuel urquhart & sullivan, lip

LOS ANGELES | 865 South Figueroa Street, 10th Floor, Los Angeles, California 90017-2543 | TEL (213) 443-3000 FAX (213) 443-3100 NEW YORK | 51 Madison Avenue, 22nd Floor, New York, New York | 10010-1601 | TEL (212) 849-7000 FAX (212) 849-7100 SAN FRANCISCO | 50 California Street, 22nd Floor, San Francisco, California 94111-4788 | TEL (415) 875-6600 FAX (415) 875-6700 CHICAGO | 500 W. Madison Street, Soite 2450, Chicago, Blinois 60661-2510 | TEL (312) 705-7400 FAX (312) 705-7401 LONDON | 16 Old Bailey, London EC4M 7EG, United Kingdom | TEL +44(0) 20 7653 2000 FAX +44(0) 20 7653 2100 TOKYO | NBF Hibiya Bldg., 25F, 1-1-7, Uchisaiwai-cho, Chiyoda-ku, Tokyo 100-0011, Japan | TEL +81 3 5510 1711 FAX +81 3 5510 1712 MANNHEIM | Erzbergerstraße 5, 68165 Mannheim, Germany | TEL +49(0) 621 43298 6000 FAX +49(0) 621 43298 6100

Fisher Scientific, Inc., Quanta Biosciences, Inc., Gene Link Inc., EMD, Trilink Biotechnologies, Inc. and Cepheid.

Following up our telephone messages, as you may know, yesterday the Federal Circuit issued *In re BP Lubricants USA Inc.*, Misc. Dkt. No. 960 (copy attached), holding that the Rule 9(b) pleading standard applies to allegations of false marking under 35 U.S.C. § 292 and that facts must be plead with particularity as to each defendant. We believe Troll Busters LLC's current complaint cannot meet the standard set forth by the Federal Circuit. Indeed, the allegations in the complaint against BP rejected by the Federal Circuit mirror the allegations in Troll Busters LLC's complaint in this action:

[R]elator contends that asserting in the complaint that BP is a "sophisticated company and has experience applying for, obtaining, and litigating patents" is enough under Rule 9(b). This court disagrees. That bare assertion provides no more of a basis to reasonably distinguish a viable complaint than merely asserting the defendant should have known the patent expired. Conclusory allegations such as this are not entitled to an assumption of truth at any stage in litigation.

Slip Op. at 8. In light of the recent BP decision, we request that Plaintiff withdraw its current complaint. We would not oppose granting Plaintiff time to consider whether it may file an amended complaint, as long as all other dates are on hold. Given that the BP decision is directly on point and compels dismissal of the complaint in its current form, we believe it would be a waste of the parties' and court's resources to prepare a motion to dismiss to the current complaint.

Sincerely yours,

In an

Brian C. Cannon

BC:ar

cc: counsel of record

Attachment